Ionis Pharmaceuticals financials
$45.89+0.70%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $267.9M | $246.1M | $203.3M | $156.7M | $452.0M | $131.6M | $226.6M | $133.8M | $225.3M | $119.5M | $324.5M | $144.2M |
| Gross profit | $265.2M | $243.1M | $195.4M | $154.4M | $447.9M | $130.1M | $222.7M | $132.7M | $221.1M | $117.3M | $321.4M | $142.0M |
| Gross margin | 99.0% | 98.8% | 96.1% | 98.5% | 99.1% | 98.9% | 98.3% | 99.2% | 98.2% | 98.2% | 99.1% | 98.5% |
| Operating income | -$102.3M | -$117.4M | -$214.5M | -$160.2M | $139.8M | -$146.9M | -$110.8M | -$148.7M | -$66.1M | -$149.5M | -$6.1M | -$143.3M |
| Net income | -$114.6M | -$92.5M | -$229.4M | -$128.6M | $123.6M | -$146.9M | -$104.3M | -$140.5M | -$66.3M | -$142.8M | -$9.3M | -$147.4M |
| Net margin | −42.8% | −37.6% | −112.8% | −82.1% | 27.3% | −111.6% | −46.1% | −105.0% | −29.4% | −119.5% | −2.9% | −102.2% |
| Diluted EPS | $-0.69 | $-0.56 | $-1.65 | $-0.80 | $0.70 | $-0.93 | $-0.66 | $-0.95 | $-0.45 | $-0.98 | $-0.06 | $-1.03 |
| EBITDA | -$98.2M | -$113.5M | -$213.0M | -$157.3M | $142.7M | -$144.1M | -$110.5M | -$145.7M | -$63.0M | -$146.3M | -$6.1M | -$140.1M |
| Operating cash flow | $565.5M | -$792.8M | -$137.7M | -$131.4M | $151.3M | -$150.8M | -$116.1M | -$115.0M | -$119.9M | -$149.9M | $32.9M | -$109.0M |
| Free cash flow | $549.5M | -$814.6M | -$159.0M | -$136.7M | $139.0M | -$163.4M | -$141.6M | -$124.0M | -$126.1M | -$154.4M | $32.0M | -$111.2M |
| Diluted shares | 165.4M | 164.9M | 139.2M | 159.8M | 182.3M | 158.7M | 158.0M | 148.6M | 146.0M | 145.5M | 143.6M | 143.3M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $350.1M | $173.4M | $372.3M | $338.3M | $297.3M | $264.2M |
| Short-term investments | $1.70B | $1.75B | $2.31B | $1.90B | $1.99B | $1.88B |
| Total debt | $1.32B | $1.75B | $1.75B | $1.20B | $1.20B | $1.25B |
| Total assets | $2.99B | $3.45B | $3.52B | $3.03B | $2.99B | $2.81B |
| Total liabilities | $2.55B | $2.96B | $3.03B | $2.42B | $2.35B | $2.34B |
| Shareholders' equity | $439.7M | $491.4M | $489.1M | $618.0M | $631.7M | $475.7M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology